This first study in humans was designed to evaluate the safety and dosimetry of a cellular
proliferative marker, N-(4-(6, 7-dimethoxy-3, 4-dihydroisoquinolin-2 (1 H)-yl) butyl)-2-(2-18F …

Several new tracers are being developed for use with PET to assess pathways that are
altered in cancers, including energy use, cellular signaling, transport, and proliferation …

3′-Deoxy-3′-18F-fluorothymidine (18F-FLT) has been recently described as a
radiopharmaceutical for measuring cellular proliferation using PET imaging. Evaluation of …

Imaging tumor cell proliferation is of high interest for both research and clinical practice in
oncology. High proliferation rates are characteristic of most malignant tumors, whereas in …

Abstract [18 F]-3′-fluoro-3′-deoxythymidine (FLT) is a nucleoside-analog imaging agent
for quantifying cellular proliferation that was first reported in 1998. It accumulates during the …

18F-Fluorocholine (fluoromethyl-dimethyl-2-hydroxyethylammonium [FCH]) has been
developed as an oncologic probe for PET. This study evaluates the kinetics and radiation …

Here we describe the evaluation of 3′-[18F] fluoro-3′-deoxythymidine {[18F]-FLT} as a
tracer for positron emission tomography (PET) in a murine model of B-cell lymphoma and in …

O-18F-fluoromethyl-d-tyrosine (d-18F-FMT) is a promising novel agent for tumor imaging by
PET. The aim of this study was to evaluate the potential of d-18F-FMT and the other …

The σ2 receptor is a potential in vivo target for measuring proliferative status in cancer. The
feasibility of using N-(4-(6, 7-dimethoxy-3, 4-dihydroisoquinolin-2 (1 H)-yl) butyl)-2-(2-18F …

Targeting cancer-associated fibroblasts (CAFs) has become an attractive goal for diagnostic
imaging and therapy because they can constitute as much as 90% of a tumor mass. The …